Reduction of acute toxicity of cyclophosphamide and X-rays by the new immunomodulating compound BM 12.531.
BM 12.531, the 2-[2-cyanaziridinyl-(1)]-2-[2-carbamoylaziridinyl-(1)]-propane, (prop. INN Azimexon), reduces significantly the acute toxicity of cyclophosphamide and X-rays in rats and mice, respectively. The leucopenia induced by X-rays was partially compensated by BM 12.531 in rats.
D000818:Animals; D001388:Aziridines / Q000494:pharmacology*; D001389:Azirines / Q000494:pharmacology*; D003520:Cyclophosphamide / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D005260:Female; D007166:Immunosuppressive Agents; D007962:Leukocytes / Q000187:drug effects; D011839:Radiation, Ionizing; D051381:Rats; D014965:X-Rays
D001388:Aziridines; D001389:Azirines; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide